SCHEMBL2808345

SCHEMBL2808345

COc1cc(C=NO)nc2c1ccc1cccnc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.45
KDM4E B2RXH2 5/20 0.43
MAPT P10636 5/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
RAB9A P51151 3/20 0.43
GAA P10253 2/20 0.43
MAPK1 P28482 2/20 0.43
HPGD P15428 2/20 0.43
PDE10A Q9Y233 1/20 0.42
CCR1 P32246 3/20 0.40
CCR5 P51681 3/20 0.40
CCR8 P51685 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
LMNA P02545 4/20 0.40
TDP1 Q9NUW8 2/20 0.40
TP53 P04637 2/20 0.40
HTT P42858 2/20 0.40
GMNN O75496 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2808343 1.00 HSP90AA1 (0.45) HSP90AA1KDM4EMAPTSMN1; SMN2MEN1
SCHEMBL2808539 0.88 MAPT (0.41) HSP90AA1KDM4EMAPTSMN1; SMN2MEN1
SCHEMBL2808536 0.88 MAPT (0.41) HSP90AA1KDM4EMAPTSMN1; SMN2MEN1
SCHEMBL2806927 0.87 MEN1 (0.40) HSP90AA1KDM4EMAPTSMN1; SMN2MEN1
SCHEMBL2806930 0.87 MEN1 (0.40) HSP90AA1KDM4EMAPTSMN1; SMN2MEN1
SCHEMBL2808446 0.83 KDM4E (0.39) HSP90AA1KDM4EMAPTSMN1; SMN2MEN1
SCHEMBL2808443 0.83 KDM4E (0.39) HSP90AA1KDM4EMAPTSMN1; SMN2MEN1
SCHEMBL3454980 0.83 HSP90AA1 (0.44) HSP90AA1KDM4EMAPTSMN1; SMN2MEN1
SCHEMBL13372636 0.83 HSP90AA1 (0.44) HSP90AA1KDM4EMAPTSMN1; SMN2MEN1
SCHEMBL3454981 0.83 HSP90AA1 (0.44) HSP90AA1KDM4EMAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140011835-A1 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES NOSCIRA, S.A. (ES) 2014-01-09 US claimed
EP-2002863-A1 [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases NOSCIRA, S.A. (ES) 2008-12-17 EP claimed
US-20140011835-A1 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES NOSCIRA, S.A. (ES) 2014-01-09 US disclosed
US-8592446-B2 [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases NOSCIRA, S.A. (ES) 2013-11-26 US disclosed
US-20100240692-A1 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES NOSCIRA, S.A. (ES) 2010-09-23 US disclosed
EP-2002863-A1 [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases NOSCIRA, S.A. (ES) 2008-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140011835-A1 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES HTT, PARK7, ATXN10 HSP90AA1 733/4885KDM4E 1412/4885MAPT 53/4885
US-20100240692-A1 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES HTT, ATXN10, PSEN1 HSP90AA1 813/4885KDM4E 1922/4885MAPT 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.